Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating selinexor with or without pembrolizumab versus standard of care in previously treated metastatic colorectal cancer with RAS mutations; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: TERMINATED | Results posted: 2023-11-03